| 1 | Pancreatic cancer | Enrichment | ATM, CHEK2, NBN, RBBP8, STK11 | 7.79 |
| 2 | Ovarian cancer | Enrichment | ATM, CHEK2, MRE11, NBN, PPM1D, RAD50, TSC2 | 7.43 |
| 3 | Breast cancer | Enrichment | ATM, CHEK2, MRE11, NBN, PPM1D, RAD50 | 6.80 |
| 4 | Inherited cancer-predisposing syndrome | Enrichment | ATM, CHEK2, MRE11, NBN, RAD50, STK11, TSC2 | 6.63 |
| 5 | Hereditary breast carcinoma | Enrichment | ATM, CHEK2, NBN, PPM1D, RAD50 | 6.50 |
| 6 | Hereditary breast ovarian cancer syndrome | Enrichment | ATM, CHEK2, MRE11, NBN, RAD50 | 6.01 |
| 7 | Colonic benign neoplasm | Enrichment | ATM, CHEK2, MRE11 | 5.55 |
| 8 | Breast-ovarian cancer, familial 1 | Enrichment | ATM, CHEK2, NBN | 5.02 |
| 9 | Glucosephosphate dehydrogenase deficiency | Enrichment | G6PD, IKBKG | 4.97 |
| 10 | Gastric cancer | Enrichment | ATM, CHEK2, NBN, STK11 | 4.93 |
| 11 | Focal cortical dysplasia, type ii | Enrichment | MTOR, TSC2 | 4.19 |
| 12 | Nijmegen breakage syndrome-like disorder | Enrichment | MRE11, RAD50 | 4.19 |
| 13 | Isolated focal cortical dysplasia type ii | Enrichment | MTOR, TSC2 | 4.19 |
| 14 | Anemia, congenital, nonspherocytic hemolytic, 1 | Enrichment | G6PD, IKBKG | 3.97 |
| 15 | Prostate cancer | Enrichment | ATM, CHEK2, NBN | 3.93 |
| 16 | Wilms tumor 5 | Enrichment | CHEK2, TRIM28 | 3.80 |
| 17 | Renal cell carcinoma, papillary, 1 | Enrichment | ATM, MTOR | 3.65 |
| 18 | Coronary heart disease 5 | Enrichment | G6PD, IKBKG | 3.42 |
| 19 | Lynch syndrome 1 | Enrichment | ATM, CHEK2 | 3.32 |
| 20 | Melanoma | Enrichment | CHEK2, STK11 | 3.32 |
| 21 | Uterine corpus cancer | Enrichment | ATM, CHEK2 | 3.24 |
| 22 | Familial colorectal cancer type x | Enrichment | ATM, CHEK2 | 3.24 |
| 23 | Nk-cell enteropathy | Enrichment | AURKB, CHEK2 | 3.09 |
| 24 | Seckel syndrome | Enrichment | ATR, RBBP8 | 3.02 |
| 25 | Renal cell carcinoma, nonpapillary | Enrichment | ATM, MTOR | 2.96 |
| 26 | Wilms tumor 1 | Enrichment | CHEK2, TRIM28 | 2.96 |
| 27 | Diffuse large b-cell lymphoma | Enrichment | CHEK2, NBN | 2.75 |
| 28 | Endometrial cancer | Enrichment | ATM, CHEK2 | 2.66 |
| 29 | Hepatocellular carcinoma | Enrichment | NBN, RAD50 | 2.62 |
| 30 | Malaria | Enrichment | G6PD, IKBKG | 2.58 |
| 31 | Colorectal cancer | Enrichment | ATM, BUB1, CHEK2 | 2.53 |
| 32 | Developmental and epileptic encephalopathy 85 with or without midline brain defects | Enrichment | SMC1A | 2.48 |
| 33 | Incontinentia pigmenti | Enrichment | IKBKG | 2.48 |
| 34 | Autoinflammatory disease, systemic, x-linked | Enrichment | IKBKG | 2.48 |
| 35 | Seckel syndrome 2 | Enrichment | RBBP8 | 2.48 |
| 36 | Seckel syndrome 1 | Enrichment | ATR | 2.48 |
| 37 | Greenberg dysplasia | Enrichment | LBR | 2.48 |
| 38 | Lissencephaly 7 with cerebellar hypoplasia | Enrichment | CDK5 | 2.48 |
| 39 | Pelger-huet anomaly | Enrichment | LBR | 2.48 |
| 40 | Rhizomelic skeletal dysplasia with or without pelger-huet anomaly | Enrichment | LBR | 2.48 |
| 41 | Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development | Enrichment | PTPA | 2.48 |
| 42 | Chromosome 2q37 deletion syndrome | Enrichment | HDAC4 | 2.48 |
| 43 | Ectodermal dysplasia and immunodeficiency 1 | Enrichment | IKBKG | 2.48 |
| 44 | Jawad syndrome | Enrichment | RBBP8 | 2.48 |
| 45 | Tumor predisposition syndrome 4 | Enrichment | CHEK2 | 2.48 |
| 46 | Riddle syndrome | Enrichment | RNF168 | 2.48 |
| 47 | Ataxia-telangiectasia-like disorder 1 | Enrichment | MRE11 | 2.48 |
| 48 | Charcot-marie-tooth disease, axonal, type 2f | Enrichment | HSPB1 | 2.48 |
| 49 | Cutaneous telangiectasia and cancer syndrome, familial | Enrichment | ATR | 2.48 |
| 50 | Immunodeficiency 26 with or without neurologic abnormalities | Enrichment | PRKDC | 2.48 |
| 51 | Seckel syndrome 6 | Enrichment | CEP63 | 2.48 |
| 52 | Endometrial serous adenocarcinoma | Enrichment | ATM | 2.48 |
| 53 | Reynolds syndrome | Enrichment | LBR | 2.48 |
| 54 | Jansen-de vries syndrome | Enrichment | PPM1D | 2.48 |
| 55 | Neurodevelopmental disorder with central hypotonia and dysmorphic facies | Enrichment | HDAC4 | 2.48 |
| 56 | Leiomyosarcoma | Enrichment | CHEK2 | 2.48 |
| 57 | Microcephaly 30, primary, autosomal recessive | Enrichment | BUB1 | 2.48 |
| 58 | Oocyte/zygote/embryo maturation arrest 21 | Enrichment | CHEK1 | 2.48 |
| 59 | B-cell non-hodgkin lymphoma | Enrichment | ATM | 2.48 |
| 60 | Congenital nonspherocytic hemolytic anemia | Enrichment | G6PD | 2.48 |
| 61 | Wilms tumor 7 | Enrichment | TRIM28 | 2.48 |
| 62 | Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome | Enrichment | ATR | 2.48 |
| 63 | Intestinal polyposis syndrome | Enrichment | STK11 | 2.48 |
| 64 | Peutz-jeghers syndrome | Enrichment | STK11 | 2.18 |
| 65 | Cornelia de lange syndrome 2 | Enrichment | SMC1A | 2.18 |
| 66 | Immunodeficiency 33 | Enrichment | IKBKG | 2.18 |
| 67 | Lymphangioleiomyomatosis | Enrichment | TSC2 | 2.18 |
| 68 | Neuronopathy, distal hereditary motor, autosomal dominant 3 | Enrichment | HSPB1 | 2.18 |
| 69 | Immunodeficiency, common variable, 12, with autoimmunity | Enrichment | NFKB1 | 2.18 |
| 70 | Congenital heart defects, multiple types, 3 | Enrichment | CHEK2 | 2.18 |
| 71 | Severe combined immunodeficiency with sensitivity to ionizing radiation | Enrichment | DCLRE1C | 2.18 |
| 72 | Neurodevelopmental disorder with dysmorphic facies, sleep disturbance, and brain abnormalities | Enrichment | KAT5 | 2.18 |
| 73 | Cardiac valvular dysplasia, x-linked | Enrichment | ATM | 2.18 |
| 74 | Cebalid syndrome | Enrichment | MTOR | 2.18 |
| 75 | Microcephaly and chorioretinopathy, autosomal recessive, 3 | Enrichment | TP53BP1 | 2.18 |
| 76 | High grade glioma | Enrichment | ATM | 2.18 |
| 77 | Li-fraumeni syndrome 1 | Enrichment | CHEK2 | 2.18 |
| 78 | Sarcoma | Enrichment | CHEK2 | 2.18 |
| 79 | Congenital hemolytic anemia | Enrichment | G6PD | 2.18 |
| 80 | Ectodermal dysplasia and immune deficiency | Enrichment | IKBKG | 2.18 |
| 81 | T-cell prolymphocytic leukemia | Enrichment | ATM | 2.18 |
| 82 | Smith-kingsmore syndrome | Enrichment | MTOR | 2.18 |
| 83 | Microcephaly and chorioretinopathy 3 | Enrichment | TP53BP1 | 2.18 |
| 84 | Common variable immunodeficiency 12 | Enrichment | NFKB1 | 2.18 |
| 85 | Ataxia-telangiectasia | Enrichment | ATM | 2.00 |
| 86 | Nijmegen breakage syndrome | Enrichment | NBN | 2.00 |
| 87 | Polycythemia vera | Enrichment | ATM | 2.00 |
| 88 | Tuberous sclerosis 1 | Enrichment | TSC2 | 2.00 |
| 89 | Polycystic kidney disease, infantile severe, with tuberous sclerosis | Enrichment | TSC2 | 2.00 |
| 90 | Osteogenic sarcoma | Enrichment | CHEK2 | 2.00 |
| 91 | Tuberous sclerosis 2 | Enrichment | TSC2 | 2.00 |
| 92 | Ehlers-danlos syndrome, kyphoscoliotic type, 1 | Enrichment | DCLRE1C | 2.00 |
| 93 | Myopathy, myofibrillar, 7 | Enrichment | CEP63 | 2.00 |
| 94 | Arthrogryposis multiplex congenita 6 | Enrichment | RIF1 | 2.00 |
| 95 | Koolen-de vries syndrome | Enrichment | ATM | 2.00 |
| 96 | Hamartoma | Enrichment | TSC2 | 2.00 |
| 97 | Testicular germ cell cancer | Enrichment | STK11 | 2.00 |
| 98 | Xanthinuria, type ii | Enrichment | TSC2 | 2.00 |
| 99 | Adenocarcinoma | Enrichment | ATM | 2.00 |
| 100 | Bone osteosarcoma | Enrichment | CHEK2 | 2.00 |
| 101 | Plod1-related kyphoscoliotic ehlers-danlos syndrome | Enrichment | DCLRE1C | 2.00 |
| 102 | Testicular cancer | Enrichment | STK11 | 2.00 |
| 103 | Apc-associated polyposis conditions | Enrichment | STK11 | 2.00 |
| 104 | Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia | Enrichment | MRE11 | 1.88 |
| 105 | Nemaline myopathy 2 | Enrichment | RIF1 | 1.88 |
| 106 | Aicardi-goutieres syndrome 1 | Enrichment | DCLRE1C | 1.88 |
| 107 | Mantle cell lymphoma | Enrichment | ATM | 1.88 |
| 108 | Tuberous sclerosis | Enrichment | TSC2 | 1.88 |
| 109 | Hemoglobin c disease | Enrichment | CHEK2 | 1.88 |
| 110 | Autosomal recessive chorioretinopathy-microcephaly syndrome | Enrichment | TP53BP1 | 1.88 |
| 111 | Oculomotor apraxia | Enrichment | ATM | 1.88 |
| 112 | Male infertility due to gonadal dysgenesis or sperm disorder | Enrichment | CHEK1 | 1.88 |
| 113 | Myeloma, multiple | Enrichment | ATM, HDAC4 | 1.83 |
| 114 | Primary ovarian insufficiency | Enrichment | CHEK2, NBN | 1.79 |
| 115 | Neuronopathy, distal hereditary motor, autosomal dominant 2 | Enrichment | HSPB1 | 1.78 |
| 116 | Familial adenomatous polyposis 1 | Enrichment | STK11 | 1.78 |
| 117 | Glioblastoma | Enrichment | ATM | 1.78 |
| 118 | Hemimegalencephaly | Enrichment | MTOR | 1.78 |
| 119 | Generalized juvenile polyposis/juvenile polyposis coli | Enrichment | STK11 | 1.78 |
| 120 | Li-fraumeni syndrome | Enrichment | CHEK2 | 1.70 |
| 121 | Testicular germ cell tumor | Enrichment | STK11 | 1.70 |
| 122 | Wiedemann-steiner syndrome | Enrichment | SMC1A | 1.70 |
| 123 | Clear cell renal cell carcinoma | Enrichment | ATM | 1.70 |
| 124 | Polycystic kidney disease 1 with or without polycystic liver disease | Enrichment | TSC2 | 1.64 |
| 125 | Polycystic kidney disease 1 | Enrichment | TSC2 | 1.64 |
| 126 | Common variable immunodeficiency | Enrichment | NFKB1 | 1.64 |
| 127 | Overgrowth syndrome | Enrichment | MTOR | 1.64 |
| 128 | Rett syndrome, congenital variant | Enrichment | SMC1A | 1.58 |
| 129 | Mosaic variegated aneuploidy syndrome | Enrichment | BUB1 | 1.58 |
| 130 | Cornelia de lange syndrome 1 | Enrichment | SMC1A | 1.53 |
| 131 | Adult hepatocellular carcinoma | Enrichment | TSC2 | 1.53 |
| 132 | Cornelia de lange syndrome | Enrichment | SMC1A | 1.53 |
| 133 | Leukemia, chronic lymphocytic | Enrichment | ATM | 1.49 |
| 134 | Omenn syndrome | Enrichment | DCLRE1C | 1.49 |
| 135 | Ciliary dyskinesia, primary, 3 | Enrichment | NFKB1 | 1.49 |
| 136 | Aplastic anemia | Enrichment | NBN | 1.49 |
| 137 | Nemaline myopathy | Enrichment | RIF1 | 1.49 |
| 138 | Immune deficiency disease | Enrichment | ATM | 1.44 |
| 139 | Leukemia, acute lymphoblastic | Enrichment | NBN | 1.44 |
| 140 | Lip and oral cavity carcinoma | Enrichment | STK11 | 1.41 |
| 141 | Premature menopause | Enrichment | NBN | 1.37 |
| 142 | Congenital nervous system abnormality | Enrichment | SMC1A, TSC2 | 1.32 |
| 143 | Nervous system disease | Enrichment | SMC1A, TSC2 | 1.32 |
| 144 | Lynch syndrome | Enrichment | CHEK2 | 1.31 |
| 145 | Autosomal dominant polycystic kidney disease | Enrichment | TSC2 | 1.31 |
| 146 | Rare genetic intellectual disability | Enrichment | MTOR | 1.31 |
| 147 | Gliosarcoma | Enrichment | ATM | 1.29 |
| 148 | Melanoma, cutaneous malignant 1 | Enrichment | STK11 | 1.26 |
| 149 | Giant cell glioblastoma | Enrichment | ATM | 1.26 |
| 150 | Semilobar holoprosencephaly | Enrichment | SMC1A | 1.24 |
| 151 | Microcephaly | Enrichment | NBN, SMC1A | 1.20 |
| 152 | Lissencephaly | Enrichment | NBN | 1.17 |
| 153 | Muscular dystrophy | Enrichment | RIF1 | 1.12 |
| 154 | Jeune thoracic dystrophy | Enrichment | LBR | 1.10 |
| 155 | Asphyxiating thoracic dystrophy | Enrichment | LBR | 1.05 |
| 156 | Bladder cancer | Enrichment | ATM | 1.04 |
| 157 | Lung cancer | Enrichment | CHEK2 | 1.00 |
| 158 | Primary autosomal recessive microcephaly | Enrichment | CEP63 | 1.00 |
| 159 | Short-rib thoracic dysplasia 1 with or without polydactyly | Enrichment | LBR | 0.98 |
| 160 | Severe combined immunodeficiency | Enrichment | DCLRE1C | 0.98 |
| 161 | Charcot-marie-tooth disease | Enrichment | HSPB1 | 0.89 |
| 162 | Hereditary spastic paraplegia | Enrichment | CEP63 | 0.88 |
| 163 | West syndrome | Enrichment | TSC2 | 0.87 |
| 164 | Autosomal dominant non-syndromic intellectual disability | Enrichment | PPM1D | 0.81 |
| 165 | Autism spectrum disorder | Enrichment | TSC2 | 0.52 |